transcatheter mitral valve repair; transcatheter mitral edge-to-edge repair (TEER)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9]

Indications

* transcatheter mitral valve repair improves survival in high surgical risk patients with severe mitral regurgitation[2]

* 5-year advantage over medical care for patients with moderate-severe mitral regurgitation[9]

Procedure

Complications

Notes

More general terms

Additional terms

References

  1. ↑ Lindenfeld J, Abraham WT, Grayburn PA et al. Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: A secondary analysis of the COAPT trial. JAMA Cardiol 2021 Feb 3; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33533873 https://jamanetwork.com/journals/jamacardiology/article-abstract/2775801
    Gillam LD. Reconciling COAPT and Mitra-FR results based on mitral regurgitation severity and left ventricular size: It's not so simple. JAMA Cardiol 2021 Feb 3; PMID: https://www.ncbi.nlm.nih.gov/pubmed/33533877 https://jamanetwork.com/journals/jamacardiology/article-abstract/2775799
  2. ↑ 2.0 2.1 Swaans MJ et al. Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. JACC Cardiovasc Interv 2014 Aug; 7:875. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25147032
    Bonow RO. The saga continues: Does mitral valve repair improve survival in secondary mitral regurgitation? JACC Cardiovasc Interv 2014 Aug; 7:882 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25147033
  3. ↑ 3.0 3.1 FDA News Release. March 14, 2019 FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633479.htm
  4. ↑ 4.0 4.1 4.2 Sorajja PSorajja P, Vemulapalli S, Feldman T et al. Outcomes with transcatheter mitral valve repair in the United States: An STS/ACC TVT registry report. J Am Coll Cardiol 2017 Nov 7; 70:2315. (http://dx.doi.org/10.1016/j.jacc.2017.09.015 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29096801
    Bolling SF. First TMVR enters U.S. market as a therapy, and a gateway. J Am Coll Cardiol 2017 Nov 7; 70:2328 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29096802
  5. ↑ 5.0 5.1 Mack MJ, Lindenfeld J, Abraham WT et al. 3-year outcomes of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol 2021 Mar 2; 77:1029. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33632476 https://www.sciencedirect.com/science/article/abs/pii/S0735109720382656
    Depta JP, Bhatt DL. Crossover in COAPT: Does this extend the reach of TMVr for treating functional MR? J Am Coll Cardiol 2021 Mar 2; 77:1041 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33632477 https://www.sciencedirect.com/science/article/abs/pii/S0735109721000036
  6. ↑ Davidson LJ, Davidson CJ Transcatheter Treatment of Valvular Heart Disease. A Review. JAMA. 2021;325(24):2480-2494 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34156404 https://jamanetwork.com/journals/jama/fullarticle/2781245
  7. ↑ 7.0 7.1 Young MN, Kearing S, Albaghdadi MA et al Trends in Transcatheter vs Surgical Mitral Valve Repair Among Medicare Beneficiaries, 2012 to 2019. JAMA Cardiol. 2022. May 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35507335 https://jamanetwork.com/journals/jamacardiology/fullarticle/2791890
  8. ↑ 8.0 8.1 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022
  9. ↑ 9.0 9.1 Stone GW et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med 2023 Mar 5; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/36876756 https://www.nejm.org/doi/10.1056/NEJMoa2300213
Retrieved from "https://aaushi.info/w/index.php?title=A57110&oldid=1147631"